Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. 

Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.

Invetx was founded in 2018 by Juergen Horn. The company is headquartered in Boston, Massachusetts.


Invetx has built an integrated, best-in-class discovery, development, and commercial manufacturing platform to create fully species-specific, optimised and half-life extended product candidates.


Invetx leverages validated biotechnologies from human health and optimising them for application in veterinary medicine, to generate differentiated antibodies to treat a wide variety of chronic and serious diseases in animals.


Invetx has also established an animal health collaboration with Vancouver-based AbCellera, which will use its proprietary platform for antibody discovery to accelerate Invetx’s preclinical activities.


Invetx is backed by F-Prime Capital, Novo Holdings, GV, Eight Roads, Anterra Capital, WuXi Biologics, Casdin Capital, AbCellera, and others. The company raised $60.5M in a Series B round on May 10, 2022. This brings Invetx's total funding to $85.8M to date.



  • Year founded: 2018
  • Funding Info: $85.8M over 3 Round (Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Boston
  • State: Massachusetts
  • Country: United States
Related businesses